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Hypercalciuria is one of the early manifestations of diabetic
nephropathy. We explored here the role of a-Klotho,
a protein expressed predominantly in distal convoluted
tubules that has a role in calcium reabsorption. We studied
31 patients with early diabetic nephropathy and compared
them with 31 patients with IgA nephropathy and 7 with
minimal change disease. Renal a-Klotho expression was
significantly lower and urinary calcium excretion (UCa/UCr)
significantly higher in diabetic nephropathy than in IgA
nephropathy or minimal change disease. Multiple regression
analyses indicated that a-Klotho mRNA was inversely
correlated with calcium excretion. We next measured
these parameters in a mouse model of streptozotocin
(STZ)-induced diabetic nephropathy, characterized by
glomerular hyperfiltration, as seen in early diabetic
nephropathy. We also confirmed a reduction of renal
a-Klotho mRNA down to almost 50% and enhanced calcium
excretion in mice with STZ-induced diabetic nephropathy
in comparison with nondiabetic mice. Hypercalciuria was
exacerbated in heterozygous a-Klotho knockout mice in
comparison with wild-type mice, each with STZ-induced
diabetic nephropathy. Thus, a-Klotho expression was
decreased in distal convoluted tubules in diabetic
nephropathy in humans and mice. Renal loss of a-Klotho
may affect urinary calcium excretion in early diabetic
nephropathy.
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Hypercalciuria is one of the early findings of uncontrolled
diabetes mellitus in both humans and experimental animal
models.1–4 Hypercalciuria is essentially associated with a
negative calcium balance hallmarked by renal calcium loss in
diabetes mellitus,1,2 which has been proposed to contribute
to the increased risk of bone fracture.5,6 Although osmotic
diuresis and increased dietary calcium intake secondary to
hyperphagia may have a role in the hypercalciuria seen in
diabetic patients,2 control of osmotic diuresis with appro-
priate insulin therapy only partially corrects hypercalciuria.7
Furthermore, increased dietary calcium intake may not
increase the calcium load on the kidney, because calcium
absorption in the gut is also decreased in the early stages of
streptozotocin (STZ)-induced diabetes.8,9 Thus, there may be
impairment in the renal handling of calcium in diabetes
mellitus. Although ultrafiltered calcium is reabsorbed in the
proximal tubules and the distal convoluted tubules (DCTs),10
previous studies have not revealed any decreases in calcium
reabsorption in the proximal tubules in diabetic models.7,11,12
Thus, DCTs may contribute to the impairment in calcium
transport,7 the underlying molecular mechanisms of which
remain unclear.
a-Klotho (a-KL) mutant mice were originally used to
model disorders associated with human aging, because the
phenotype of the mutant animals includes arteriosclerosis,
ectopic calcification (including vascular calcification),
emphysema, and osteoporosis.13 The a-KL gene is predomi-
nantly expressed in the parathyroid glands, the DCTs in the
kidney, and the choroid plexus in the brain,14,15 all of which
have an important role in calciumphosphorus homeo-
stasis. Recently, evidence has accumulated showing that a-KL
regulates (1) parathyroid hormone (PTH) release in the para-
thyroid gland,14 (2) the production of 1,25(OH)2 vitamin D3
by negatively regulating the expression of 1a-hydroxylase,
which encodes a rate-limiting enzyme of active vitamin D
synthesis,16,17 and (3) transepithelial calcium transport in the
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DCTs via activation of the transient receptor potential
vanilloid 5 (TRPV5) channel.18 In fact, mice lacking a-KL
display diminished renal calcium reabsorption, resulting in
severe hypercalciuria.19
In this study, we showed that renal a-KL expression levels
were decreased in patients with early diabetic nephropathy
(DN) and in the STZ-induced mouse model of diabetes, and
that renal a-KL expression levels were inversely correlated
with urinary calcium augmentation in patients with DN and
a mouse model of DN. Furthermore, we confirmed the
exaggerated urinary excretion of calcium in STZ-induced DN
in heterozygous a-KL knockout mice (a-KLþ / mice). Thus,
we propose that renal a-KL expression levels are partially
involved in hypercalciuria in early DN.
RESULTS
Elevation of urinary calcium excretion (UCa/UCr) in patients
with DN
Urinary calcium excretion (UCa/UCr), which was normal-
ized to the urinary creatinine, was significantly higher in
patients with DN than in those with either IgA nephropathy
(IgAN) or minimal change disease (MCD) (DN, 0.081±
0.044; IgAN, 0.037±0.021; MCD, 0.039±0.022; Po0.001;
Figure 1a). Serum calcium concentrations were similar
among the three patient groups (Table 1). On considering
the population subset with an estimated glomerular filtration
rate (eGFR) greater than 60ml/min per 1.73m2, UCa/UCr
levels in DN were highly elevated relative to those seen in
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Figure 1 | Elevation of urinary calcium excretion (UCa/UCr) in patients with diabetic nephropathy (DN). (a) UCa/UCr, (b) serum
1,25(OH)2 vitamin D3 concentration, and (c) serum intact parathyroid hormone (i-PTH) concentration were measured in patients with DN
(black bars), IgA nephropathy (IgAN) (striped bars), or minimal change disease (MCD) (white bars). Data are shown as means±s.e.m. for
each group. KruskalWallis analysis of variance by ranks with Bonferroni adjustment was used to compare groups. *Po0.001; **Po0.01.
Table 1 | Clinical characteristics of study population
DN IgAN MCD
Number of patients 74 90 26
Age (years) 64±10w 40±16 35±16
Serum creatinine (mg/dl) 0.95±0.48 0.85±0.31 0.82±0.22
eGFR (ml/min per 1.73m2)a 74.4±24.9 79.2±23.9 87.2±22.5z
Corrected serum calcium (mg/dl) 9.4±0.4 9.3±0.3 9.5±0.4
Abbreviations: DN, diabetic nephropathy; eGFR, estimated glomerular filtration rate;
IgAN, IgA nephropathy; MCD, minimal change disease.
Clinical parameters are presented as means±s.d.
aeGFR was calculated by means of the creatinine-based Modification of Diet in Renal
Disease Study Equation. wPo0.05 vs. IgAN or MCD. zPo0.05 vs. DN.
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IgAN and MCD (DN, 0.086±0.047; IgAN, 0.032±0.020;
MCD, 0.038±0.024; Po0.001; Figure 1a). In patients with
an eGFR under 60ml/min per 1.73m2, however, there was
no significant difference in UCa/UCr levels between DN,
IgAN, and MCD (DN, 0.062±0.021; IgAN, 0.054±0.013;
MCD, 0.045±0.009; P¼ 0.265; Figure 1a). Serum levels
of 1,25(OH)2 vitamin D3 were significantly lower in DN than
in IgAN and MCD (DN, 41.69±16.1 pg/ml; IgAN, 48.18±
12.51 pg/ml; MCD, 50.2±12.6 pg/ml; P¼ 0.004; Figure 1b).
In the population with an eGFR greater than 60ml/min per
1.73m2, however, serum 1,25(OH)2 vitamin D3 levels were
lower in DN, as compared with IgAN and MCD, but this
decrease was not significant (DN, 45.86±14.88 pg/ml; IgAN,
50.00±11.87 pg/ml; MCD, 52.61±10.95 pg/ml; P¼ 0.069;
Figure 1b). Serum intact PTH (i-PTH) values were
significantly increased in DN in comparison with those in
IgAN for both the total study population (DN, 39.2±
15.19 pg/ml; IgAN, 33.68±11.79 pg/ml; MCD, 35.23±
9.96 pg/ml; P¼ 0.027, Figure 1c) and the population subset
with an eGFR greater than 60ml/min per 1.73m2 (DN,
36.53±13.65 pg/ml; IgAN, 31.16±10.20 pg/ml; MCD,
33.09±7.99 pg/ml; P¼ 0.032; Figure 1c).
Reduction in a-KL expression in the early stages of human DN
In immunohistological examination, although a-KL reactiv-
ity was detectable exclusively in DCTs in patients with MCD
and IgAN (Figure 2b and c), the reactivity was significantly
reduced in samples from DN patients (Figure 2a). a-KL
reactivity was also detected in the proximal convoluted
tubules, although the reactivity in proximal convoluted
tubules was weaker than that in DCTs. a-KL immunoreactivity
in proximal convoluted tubules was similar to that in DN,
IgAN, and MCD. Renal a-KL mRNA expression levels,
quantitatively measured by real-time PCR, were significantly
correlated with eGFR (r¼ 0.353, P¼ 0.0034; Figure 2e),
suggesting that renal a-KL mRNA expression levels were
decreased with the advance of renal failure. Notably, looking at
the population with an eGFR greater than 60ml/min per
1.73m2, renal a-KL mRNA expression levels were markedly
decreased in the presence of DN in comparison with IgAN
and MCD (DN, 0.45±0.27AU; IgAN, 1.07±0.45AU; MCD,
1.29±0.58AU; P¼ 0.0004; Figure 2f). However, in the popu-
lation subset with an eGFR under 60ml/min per 1.73m2, renal
a-KL mRNA expression levels were similar to those in DN,
IgAN, and MCD (Figure 2f).
Next, we used the same renal biopsy specimens to
investigate the degree of renal tubulointerstitial damage
progression in the DN, IgAN, and MCD groups. Neither the
average numbers of CD31-positive peritubular capillaries
(PTCs) nor the percentage of type I collagen–positive areas
per single field in DN were significantly different from those
seen in IgAN or MCD when the eGFR was greater than
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Figure 2 |Reduction in a-Klotho (a-KL) expression in human early diabetic nephropathy (DN). (a–d) Representative immunoperoxidase
staining for a-KL protein in renal biopsy sections from human patients with DN, IgA nephropathy (IgAN), or minimal change disease (MCD),
and negative control (MCD treated with rat immunoglobulins instead of rat anti-a-KL antibody). Original magnification,  100. (e)
Correlation of renal a-KL mRNA expression levels with estimated glomerular filtration rate (eGFR) in patients with DN (closed circles) and
IgAN and MCD (open circles). (f) Renal a-KL mRNA expression levels in DN (black bars), IgAN (striped bars), and MCD (white bars). Data are
shown as means±s.e.m. for each group. KruskalWallis analysis of variance by ranks with Bonferroni adjustment was used to compare
groups. *Po0.01.
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60ml/min per 1.73m2 (CD31-positive PTC numbers: DN,
50.6±18.9; IgAN, 55.2±12.8; MCD, 66.8±10.6; P¼ 0.174;
Figure 3a; Type I collagen positive areas: DN, 11.7±3.5%,
IgAN 10.4±3.2%, MCD 8.7±3.2%; P¼ 0.234; Figure 3b).
Correlation of renal a-KL mRNA expression levels with
UCa/Ucr
An examination of three clinical parameters governing
calcium metabolism—levels of renal a-KL expression, serum
1,25(OH)2 vitamin D3, and serum i-PTH—showed that levels
of renal a-KL mRNA expression (r¼0.642, Po0.0001),
serum 1,25(OH)2 vitamin D3 (r¼0.334 P¼ 0.0054), and
serum i-PTH (r¼ 0.274, P¼ 0.0244) correlated significantly
with UCa/UCr across all patients with DN, IgAN, and
MCD, who had undergone renal biopsy (Figure 4). Multiple
regression analyses revealed that renal a-KL expression levels
were significantly and inversely correlated with UCa/UCr
(b¼ 10.644, Po0.0001) as an independent variable in order of
importance (R2¼ 0.375, Po0.0001), but serum 1,25(OH)2
vitamin D3, serum i-PTH, serum calcium, eGFR, and age were
not (Table 2), among all patients who had undergone renal
biopsy. In patients with an eGFR greater than 60ml/min per
1.73m2, univariate analysis showed that renal a-KL mRNA
expression levels correlated significantly with only UCa/UCr
(r¼0.755, Po0.0001; data not shown).
Development of DN in STZ-treated mice
In this human study, we revealed a significant decrease in
renal a-KL expression levels and an increase in UCa/UCr in
DN with an eGFR greater than 60ml/min per 1.73m2.
Therefore, to confirm that renal a-KL expression levels were
decreased in early DN, and that this decrease was related to
elevations in UCa/UCr, we used the STZ-induced mouse
model of diabetes. In this model mouse, urinary albumin to
creatinine ratios were increased at 2, 4, 6, and 8 weeks after
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Figure 3 | The degree of renal tubulointerstitial damage
progression in the diabetic nephropathy (DN), IgA
nephropathy (IgAN), and minimal change disease (MCD).
(a) The average number of CD31-positive peritubular capillaries
(PTCs) and (b) the average proportion of type I collagen-positive
areas per field in renal biopsy specimens from patients with DN
(black bars), IgAN (striped bars), and MCD (white bars). Data are
shown as means±s.e.m. for each group. KruskalWallis analysis
of variance by ranks with Bonferroni adjustment was used to
compare groups.
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Figure 4 |Correlation of renal a-Klotho (a-KL) mRNA
expression levels with urinary calcium excretion (UCa/UCr).
(a) UCa/UCr with renal a-KL mRNA expression indices (r¼0.642,
Po0.0001), (b) serum 1,25(OH)2 vitamin D3 concentrations
(r¼0.334, P¼ 0.0054), and (c) serum intact-parathyroid
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who had undergone renal biopsy. Correlations were evaluated
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the establishment of diabetes (Supplementary Figure S1
online). This diabetic mouse model did not show apparent
histopathological findings characteristic with DN at 8 weeks
after the establishment of diabetes, indicating to be a useful
model for early DN (Supplementary Figure S2 online).
Decrease in renal a-KL expression levels and elevation of
UCa/UCr in STZ-induced diabetic mice
In STZ-induced diabetic mice, renal a-KL mRNA expression
levels were maintained until 4 weeks after the establishment
of diabetes mellitus, but they decreased significantly to about
70% of the levels of nondiabetic control mice at 6 weeks and
to about 50% at 8 weeks (Po0.001, Figure 5c). This decrease
was also confirmed at the protein level by immunohisto-
logical examination and western blotting (Figure 5a and b).
UCa/UCr in diabetic mice was slightly but significantly
increased beginning 2 weeks after the establishment of
diabetes mellitus, and it was further elevated at 6 and
8 weeks (Po0.001; Figure 5d). Interestingly, the levels of
UCa/UCr in diabetic mice at 6 weeks significantly increased
to about one and a half times as much as those in diabetic
mice at 4 weeks, and these levels at 8 weeks showed a further
significant increase to about two times as much as those
at 4 weeks (Figure 5d). Thus, the reduction of renal a-KL
expression in STZ-induced diabetic mice may be related to
further enhancement of UCa/UCr levels.
Exaggeration of UCa/UCr in STZ-induced diabetic
a-KLþ / mice
To confirm whether or not the approximately 50% reduction
in renal a-KL expression resulted in an elevation in
UCa/UCr, we measured this excretion in a-KLþ / mice.
There were no significant differences in UCa/UCr levels
between a-KLþ / and a-KLþ /þ mice (Figure 6a). Next, we
examined STZ-induced DN in a-KLþ / mice. To avoid the
DN-related decline of renal a-KL expression, we examined
UCa/UCr beginning 2 weeks after the establishment of diabetes
mellitus in both diabetic a-KLþ /þ and a-KLþ /mice. During
the first 2 weeks, although renal a-KL expression levels were
similar in diabetic and nondiabetic mice of both genotypes
(Figure 6b and c), UCa/UCr levels in diabetic a-KLþ / mice
increased to about one and a half times as much as those in
diabetic a-KLþ /þ mice (Po0.001; Figure 6a). Thus, when
diabetes was induced, the 50% reduction in renal a-KL
expression may be related to the greater increases in UCa/UCr
levels in a-KLþ / mice than those in a-KLþ /þ mice.
The effect of a-KL expression levels on the activity
of TRPV5
TRPV5 is predominantly involved in renal calcium handling.
TRPV5 colocalizes with a-KL in DCTs, and its activity is
stimulated by a-KL.18 Therefore, to investigate the mechan-
ism by which the reduction of renal a-KL expression is
related to the increase of urinary calcium excretion, we
studied the effect of a-KL expression on TRPV5 activity.
First, we verified that the level of renal TRPV5 expression was
not significantly lower in DN with an eGFR greater than
60ml/min per 1.73m2 than in IgAN or MCD, and also not
lower in STZ-induced diabetic mice at 8 weeks than
nondiabetic mice (Figure 7a–d), indicating that there is no
significant association between the levels of a-KL expression
and those of TRPV5 expression in the kidney. Next, to clarify
whether or not TRPV5 channel activity is associated with the
level of a-KL expression, we transfected both TRPV5 and
various amounts of adenoviral vectors carrying the a-KL gene
into human embryonic kidney 293 (HEK293) cells, and then
Table 2 |Multiple regression analysisa for urinary calcium
excretion (UCa/UCr)
Independent variable bw P-value
Renal a-Klotho expression levels 0.644 o0.0001
Serum 1,25(OH)2 vitamin D3 0.048 0.7131
Serum intact-PTH 0.151 0.1952
eGFR 0.05 0.7207
Corrected serum calcium 0.035 0.7268
Age 0.047 0.6961
Abbreviations: eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone;
UCa/UCr, urinary calcium (mg/dl)/urinary creatinine (mg/dl).
aAdjusted coefficient of determination (R2); R2=0.375, Po0.0001.
wStandard partial regression coefficient.
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Figure 5 |Decrease in renal a-Klotho (a-KL) expression levels
and elevation of urinary calcium excretion (UCa/UCr) in
streptozotocin (STZ)-induced diabetic mice. (a) Representative
immunoperoxidase staining for a-KL in kidney specimens, and
(b) western blotting to detect a-KL of the kidney from the
indicated mice. (c) Time course of renal a-KL mRNA expression
levels and (d) time course of the urinary calcium (mg/dl) to
creatinine (mg/dl) ratio in diabetic (closed circles) and nondiabetic
(open circles) mice. Original magnification,  100. Student’s t-test
was used to compare groups. *Po0.001, vs. nondiabetic mice;
**Po0.05, vs. STZ-treated mice 4 weeks after the establishment
of diabetes.
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analyzed calcium uptake in the transfectants. In this in vitro
experiment, we showed that, in HEK293 transfected with
both TRPV5 and a-KL gene, calcium uptake was significantly
increased in proportion to the a-KL expression (Figure 7e).
In this experiment, HEK293 cells transfected with both
TRPV5 and Lac Z gene served as the control. We also found
that calcium uptake did not significantly increase in HEK293
cells in the absence of TRPV5, even when a-KL expression
was elevated (Figure 7e).
DISCUSSION
This study demonstrated, for the first time, that renal
a-KL expression levels in patients with DN were markedly
decreased in comparison with those in patients with either
IgAN or MCD with an eGFR greater than 60ml/min per
1.73m2. We confirmed that UCa/UCr in patients with DN
was markedly increased in comparison with patients with
IgAN or MCD, and renal a-KL expression levels correlated
significantly with UCa/UCr in humans. In the STZ-induced
mouse model of diabetes, we also observed that the decreases
in renal a-KL expression levels correlated with greater
enhancement of UCa/UCr. Moreover, we confirmed the
exacerbated renal calcium loss in KLþ / mice with STZ-
induced DN. These findings indicate for the first time a
significant correlation between renal a-KL loss and hyper-
calciuria in early DN.
Our study revealed that renal a-KL expression levels were
significantly decreased in patients of DN with an eGFR greater
than 60ml/min per 1.73m2. Although eGFR is grossly related
to the degree of renal tubulointerstitial damage, eGFR may not
always be correlated with renal tubulointerstitial damage
because of the development of glomerular hyperfiltration in
the early stages of DN.20,21 To exclude the possibility that
increased tubulointerstitial damage was responsible for the
observed decreases in renal a-KL expression in DN, we
immunohistologically investigated PTC counts and the degree
of interstitial fibrosis.22,23 In the population of patients with an
eGFR greater than 60ml/min per 1.73m2, we did not observe
any significant histological differences in tubulointerstitial
damage among DN, IgAN, and MCD specimens. In addition
to human examination, we confirmed the reduced expression
of a-KL mRNA in the kidneys of STZ-induced diabetic mice,
in which apparent glomerular and tubulointerstitial injury
were not detected. These results suggest that a reduction
of renal a-KL expression in the early stages of DN is a
characteristic finding of DN.
Hypercalciuria is also an early finding characteristic of
patients with DN,1 and renal tubular calcium excretion is
indicated to be increased in STZ-induced diabetes mellitus,
despite exhibiting normal plasma calcium concentrations.2–4
The precise mechanism of hypercalciuria in DN, however,
remains unclear. In the present study, multiple regression
analyses clearly showed that the renal expression of a-KL
mRNA is an independent determinant of UCa/UCr, and the
reduction of renal a-KL expression in STZ-induced diabetic
mice was shown to enhance the diabetes-related increase of
UCa/UCr levels. Thus, it is possible that the decline of a-KL
mRNA in DCTs is responsible for the increase of UCa/UCr
observed in DN. Given the evidence that a-KL/ mice
showed a tremendous increase in UCa/UCr,19 this scenario is
plausible but not evident, because the reduction of a-KL
mRNA levels was at most 50% in the diabetic patients and
mouse model of diabetes.
To confirm the scenario, we investigated UCa/UCr levels
in a-KLþ / mice. Half reduction of a-KL expression per se
did not lead to hypercalciuria in a-KLþ / mice. However,
when we induced diabetes by STZ injection in a-KLþ / and
a-KLþ /þ mice, diabetes-induced increment of UCa/UCr
levels was significantly larger in a-KLþ / mice than in
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Figure 6 | Exaggeration of urinary calcium excretion (UCa/UCr)
in streptozotocin (STZ)-induced diabetic a-Klotho (a-KL)+/–
mice. (a) UCa/UCr in diabetic and nondiabetic mice of a-KLþ /
(black bars) and a-KLþ /þ (white bars) strains. (b) Western blotting
for a-KL in kidney specimens from the indicated mice, and (c)
renal a-KL mRNA expression indices in diabetic and nondiabetic
mice of a-KLþ / (black bars) and a-KLþ /þ (white bars) strains.
Student’s t-test was used to compare groups. *Po0.001.
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a-KLþ /þ mice within 2 weeks after the establishment
of diabetes mellitus, even when DN-related further decline
of a-KL expression was not detected (Figure 6). Therefore,
the increased UCa/UCr levels in the diabetic patients and
mouse model of diabetes result from not only some diabetes-
related changes such as glomerular hyperfiltration of calcium
but also the 50% reduction in renal a-KL mRNA expression.
Thus, hypercalciuria in the early stages of DN is at least partly
due to a-KL loss in DCT.
Recently, evidence has accumulated that TRPV5 and Naþ /
Kþ -ATPase were carriers to mediate the activity of a-KL on
calcium excretion in the DCTs.14,18,24 Our in vitro analyses
showed that, in HEK293 cells transfected with both TRPV5
and a-KL, calcium uptake was significantly increased in
proportion to the a-KL expression, indicating that the
reduction of a-KL expression may be related to a reduced
abosorption of calcium via TRPV5 channels in the DCTs.
This effect could reduce the capacity for calcium reabsorp-
tion in the DCTs to a level insufficient to meet the demand
of the glomerular hyperfiltrated calcium in DN, which would
in turn lead to more increasing urinary calcium excretion
as a-KL expression levels decline. However, the other mole-
cules including Naþ /Kþ -ATPase may mediate the activity of
a-KL on calcium excretion in the kidney, and further studies
will be needed to more precisely clarify these underlying
mechanism.
In conclusion, a-KL expression levels in the DCTs are
decreased in the early stages of DN, which may affect urinary
excretion of calcium in early DN.
MATERIALS AND METHODS
Study population
This study evaluated 74 patients with DN who manifested micro-
albuminuria, macroalbuminuria, and/or overt proteinuria, 90
patients diagnosed with IgAN by renal biopsy, and 26 patients with
MCD. Spot urine and serum samples were collected between 0600
and 1000 h after a 10-h overnight fast. Serum levels of total protein,
albumin, creatinine, calcium, inorganic phosphate, and glucose, as
well as urinary levels of protein, creatinine, calcium, and inorganic
phosphate, were measured in all patients. Serum 1,25(OH)2
vitamin D3 levels were measured by radioimmunoassay, and serum
i-PTH levels were measured by ECLIA (SRL, Tokyo, Japan). Serum
fibroblast growth factor 23 concentrations were measured by
using an ELISA kit (Kainos laboratories, Tokyo, Japan). eGFR was
calculated by the creatinine-based Modification of Diet in Renal
Disease Study equation.25 Patient characteristics are listed in Table 1.
In this study population, we evaluate renal a-KL expression levels in
31 patients with DN who had undergone renal biopsy, 31 patients
with IgAN, and 7 patients with MCD. Renal biopsy had been
performed in patients, whose amount of urinary protein was over
0.5 g/day. The patient characteristics of this subset used to evaluate
renal a-KL expression are listed in Supplementary Table online.
All clinical study protocols were approved by our institutional
ethics committee (No. 2002-009, Nara Medical University Ethics
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Figure 7 | The effect of a-KL expression levels on the activity of transient receptor potential vanilloid calcium channel subtype 5
(TRPV5). (a) Representative immunoperoxidase staining for TRPV5 in renal biopsy sections from human patients with diabetic nephropathy
(DN), IgA nephropathy (IgAN), and minimal change disease (MCD). (b) Renal TRPV5 mRNA expression levels in DN (black bars), IgAN (striped
bars), and MCD (white bars). (c) Representative immunoperoxidase staining for TRPV5 in kidney specimens from the indicated mice.
(d) Renal TRPV5 mRNA expression levels in STZ diabetic (black bars) and nondiabetic (white bars) mice. (e) 45Ca2þ uptake in HEK293 cells
transfected with adenovirus carrying the a-KL gene (a-KL-Ad) or Lac Z gene as control, at the indicated doses, with or without TRPV5
expression. (f) Western blotting and (g) mRNA expression levels of a-KL (black bars) and TRPV5 (white bars) in the indicated HEK293 cells.
Data are shown as means±s.e.m. for each group. Original magnification,  100. Student’s t-test was used to compare groups. #Po0.05,
vs. HEK293 cells without TRPV5 and a-KL gene transfected; *Po0.05, vs. HEK293 cells transfected with TRPV5 and Lac Z.
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Committee). Written informed consent was obtained in all cases
from either the patient or his or her family members.
Animal studies
C57BL/6 mice, originally obtained from Japan Clea (Tokyo, Japan),
and a-KLþ / mice15 were housed under specific pathogen-free
conditions in the Animal Research Institute of Nara Medical
University. Diabetes was induced in both adult male C57BL/6 mice
and a-KLþ / mice at 8 weeks of age by intraperitoneal injections of
STZ (200mg/kg) as previously reported.26 Mice were individually
housed in metabolic cages to obtain 24-h urine collections before
killing. Commercial kits were used to measure concentrations of
urine creatinine and calcium (Creatinine-Test and Calcium E-Test
Wako, Wako, Wako Pure Chemical Industries, Osaka, Japan), as well
as albumin (Albuwell M, Exocell, Philadelphia, PA). All procedures
involving mice were performed in accordance with the National
Institutes of Health guidelines for the care and use of live animals
and were approved by the Nara Medical University Animal Care
Committee.
Immunohistochemical studies
a-KL was immunohistochemically labeled using KM2076 antibody
(1:50 dilution; a kind gift of Kyowa Hakko Kogyo);27 human type I
collagen was labeled using mouse anti-human collagen type I mono-
clonal antibodies (1:500 dilution; MP Biomedicals, LLC, Solon,
OH); TRPV5 was labeled using rabbit anti-rat TRPV5 polyclonal
antibodies (1:100 dilution; Alpha Diagnostic International, San
Antonio, TX) in sections from human renal biopsy specimens and
murine kidneys. Human CD31, a marker of PTCs, was labeled using
mouse anti-human CD31 monoclonal antibodies (1:100 dilution;
Dako, Glostrup, Denmark). After primary antibody staining,
labeling was visualized using a Dako Envison Kit. The number of
CD31-positive PTCs within the confines of each of 10 random fields
(delineated by a 1-cm2 ocular grid viewed at  100 magnification)
was expressed as a mean per field. We also evaluated the mean
percentages of each of 10 random fields positive for type I collagen
by using an auto-analyzer.
DNA constructs
The coding sequence of wild-type TRPV5 was amplified from mouse
(strain C57BL/6) kidney cDNA and cloned into the pcDNA3 vector
(TRPV5-pcDNA3 vector). The coding sequence of wild-type a-KL
was amplified from mouse (strain C57BL/6) kidney cDNA, and
recombinant adenoviral vector carrying a-KL gene (adeno-a-KL) was
constructed using the Adeno-X expression system according to the
manufacturer’s protocol (Clontech laboratories, Mountain View, CA).
All constructs were verified by DNA sequence analysis.
Cell transfection and 45Ca2þ uptake assay
HEK293 cells were transfected with TRPV5-pcDNA3 vector using
the FuGENE HD transfection reagent according to the manufac-
turer’s protocol (Roche, Mannheim, Germany), and cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine
serum, and infected with adeno-a-KL and the control adeno-Lac Z,
respectively, in a six-well plate. Two days after transfection, 45Ca2þ
(1 uCi/ml) uptake was performed as described previously.28,29
Western blotting
Kidney and cell lysates were prepared using lysis buffer, and
western blot analysis was performed as previously reported,27,29
using specific antibodies, including monoclonal rat antibody for
a-KL protein (KM2076)27 (1:500 dilution) and polyclonal
rabbit antibody for TRPV5 protein (1:100; Alpha Diagnostic
International).
RNA extraction, reverse transcription, and real-time RT-PCR
Total cellular RNA was extracted from human frozen renal
biopsy specimens, murine renal cortex, or HEK293 cells, and
first-strand cDNA was constructed as previously described.30,31 For
real-time PCR, 1 ml of each first-strand reaction product was ampli-
fied with appropriate primers and the corresponding fluorescent
probes for human and murine a-KL (assay IDs: Hs00183100_m1,
Mm00502002_m1) and TRPV5 (assay IDs: Hs00219765_m1,
Mm01166029_m1), human b-actin (assay ID: Hs00242273_m1),
or murine glyceraldehydes-3-phosphate dehydrogenase (assay ID:
Mm99999915_m1). These probes were designed by the Applied
Biosystems ‘Assay-on-Demand’ service (Foster City, CA). The ratios
of human a-KL/b-actin mRNA, human TRPV5/b-actin mRNA,
murine a-KL/glyceraldehydes-3-phosphate dehydrogenase mRNA,
and murine TRPV5/glyceraldehydes-3-phosphate dehydrogenase
mRNA were calculated for each sample.
Statistical analysis
Statistical analyses were performed with the StatView 5.0 software
(SAS Institute, Cary, NC). Numerical results were expressed as
means±s.d. Student’s t-test was used for normally distributed
variables. To compare groups, we used a one-way analysis of
variance, followed by post-hoc t-test with Fisher-Protected Least
Significant Differences adjustment. For variables with a skewed
distribution, we used a KruskalWallis analysis of variance by
ranks with Bonferroni adjustment. The Pearson correlation
coefficient was used to assess the relationships between renal a-KL
mRNA expression levels and clinical and pathological parameters.
Multiple regression analysis was performed to assess the combined
influence of clinical variables on UCa/UCr among all patients
with DN, IgAN, and MCD, who had undergone renal biopsy.
Independent variables included levels of renal a-KL expression,
serum 1,25(OH)2 vitamin D3, serum i-PTH, corrected serum
calcium, as well as eGFR and age. P-values less than 0.05 were
considered to be significant.
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SUPPLEMENTARY MATERIAL
Figure S1. Time course of urinary albumin to creatinine ratios
(UACR) in diabetic (closed circles) and nondiabetic (open circles)
mice.
Figure S2. Representative features of STZ-induced diabetic (a, b, c)
and nondiabetic (d, e, f) mouse kidneys (periodic acid–methenamine–
silver stain) at 0 weeks (a, d), 4 weeks (b, e), and 8 weeks (c, f) after the
establishment of diabetes.
Table S1. Clinical characteristics of patients for renal a-KL expression
analysis.
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